Trial RBR–9nn3scw
Publication Costa Clemens SA, Lancet, 2022
Primary outcome on the report: Non-inferiority of anti-spike IgG antibodies 28 days after the booster dose

Note: The risk of bias by domain corresponds to the highest risk of bias among outcomes by domain.
The overall risk of bias corresponds to the overall highest risk of bias assessed among outcomes.